Laurus Labs Limited
NSE: LAURUSLABS BSE: LAURUSLABS
NSE
640.35
12.30 (1.96%)
Prev Close
628.05
Open Price
628.05
Volume
1,671,228
Today Low / High
627.45 / 645
52 WK Low / High
385.45 / 646.2
Range
608 - 672
BSE
640.25
12.90 (2.06%)
Prev Close
627.35
Open Price
627.4
Volume
80,312
Today Low / High
627.4 / 643.95
52 WK Low / High
386.85 / 646.25
Range
608 - 672
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 640.35 (target range: 608 - 672), reflecting a change of 12.3 (1.95844%). On the BSE, it is listed at 640.25 (target range: 608 - 672), showing a change of 12.9 (2.05627%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
21 Apr
628.05
1.96%
17 Apr
626.80
0.20%
16 Apr
625.50
0.22%
15 Apr
611.55
2.22%
11 Apr
585.00
3.56%
09 Apr
564.25
0.00%
08 Apr
579.00
0.04%
07 Apr
518.00
8.35%
04 Apr
620.65
-7.44%
03 Apr
620.15
0.08%
02 Apr
604.00
0.84%
01 Apr
611.00
-1.98%
28 Mar
619.90
-1.05%
27 Mar
614.50
0.52%
26 Mar
614.00
0.13%
25 Mar
626.70
-1.84%
24 Mar
620.95
0.33%
Laurus Labs Limited Graph
Laurus Labs Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Laurus Labs Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 640.35, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 640.25 | 646.65 | 581.99 - 711.32 |
| 653.06 | 522.44 - 783.67 | ||
| 659.46 | 461.62 - 857.29 | ||
| Bearish Scenario | 640.25 | 633.85 | 570.46 - 697.23 |
| 627.45 | 501.96 - 752.93 | ||
| 621.04 | 434.73 - 807.36 |
Overview of Laurus Labs Limited
ISIN
INE947Q01028
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
3,204,786
Market Cap
345,310,338,375
Last Dividend
0.8
Official Website
IPO Date
2016-12-19
DCF Diff
635.28
DCF
-2
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 5,001.80 Cr | 2,539.79 Cr | 2,462.01 Cr | 0.4922 | 43.76 Cr | 66.63 Cr | 394.86 Cr | 160.55 Cr | 2.98 | 800.60 Cr | 0.0321 |
| 2023-03-31 | 6,040.55 Cr | 2,774.32 Cr | 3,266.23 Cr | 0.5407 | 25.59 Cr | 63.82 Cr | 1,294.68 Cr | 790.11 Cr | 14.69 | 1,575.61 Cr | 0.1308 |
| 2022-03-31 | 4,888.54 Cr | 2,248.32 Cr | 2,640.22 Cr | 0.5401 | 29.47 Cr | 61.80 Cr | 1,175.06 Cr | 827.52 Cr | 15.42 | 1,427.30 Cr | 0.1693 |
| 2021-03-31 | 4,723.22 Cr | 2,197.37 Cr | 2,525.85 Cr | 0.5348 | 17.29 Cr | 48.94 Cr | 1,350.65 Cr | 983.58 Cr | 18.36 | 1,572.56 Cr | 0.2082 |
| 2020-03-31 | 2,758.61 Cr | 1,444.03 Cr | 1,314.58 Cr | 0.4765 | 15.18 Cr | 44.25 Cr | 383.15 Cr | 255.27 Cr | 4.79 | 559.48 Cr | 0.0925 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 138.94 Cr | 8,387.03 Cr | 4,271.46 Cr | 4,110.9500 Cr | 2,577.40 Cr | 2,438.46 Cr | 1,845.41 Cr | 4,047.53 Cr | 81.85 Cr | 0.00 Cr | 123.98 Cr | 3,112.2800 Cr |
| 2023-03-31 | 45.67 Cr | 7,660.40 Cr | 3,611.74 Cr | 4,037.5300 Cr | 2,015.09 Cr | 1,969.42 Cr | 1,684.81 Cr | 3,700.17 Cr | 277.42 Cr | 125.50 Cr | 49.90 Cr | 2,432.2600 Cr |
| 2022-03-31 | 75.35 Cr | 6,968.04 Cr | 3,608.99 Cr | 3,351.1900 Cr | 1,776.66 Cr | 1,701.31 Cr | 1,760.30 Cr | 3,208.56 Cr | 616.06 Cr | 67.03 Cr | 30.81 Cr | 2,681.0100 Cr |
| 2021-03-31 | 48.46 Cr | 5,750.69 Cr | 3,149.99 Cr | 2,597.5500 Cr | 1,481.69 Cr | 1,433.23 Cr | 1,575.45 Cr | 2,277.17 Cr | 222.68 Cr | 71.84 Cr | 3.41 Cr | 2,457.1500 Cr |
| 2020-03-31 | 1.69 Cr | 3,750.32 Cr | 1,980.54 Cr | 1,769.7780 Cr | 1,079.43 Cr | 1,077.74 Cr | 905.22 Cr | 1,774.02 Cr | 169.12 Cr | 56.74 Cr | 3.41 Cr | 1,692.3660 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 665.6900 Cr | -822.4200 Cr | 249.8300 Cr | -12.6200 Cr | 93.2700 Cr | 138.9400 Cr | -678.3100 Cr | 160.5500 Cr | 541.0500 Cr | -86.1800 Cr | -151.3100 Cr |
| 2023-03-31 | 993.9000 Cr | -996.0600 Cr | -26.6400 Cr | 3.7400 Cr | -29.6800 Cr | 45.6700 Cr | -990.1600 Cr | 1,108.9400 Cr | 221.6200 Cr | -107.4700 Cr | 81.8300 Cr |
| 2022-03-31 | 911.1000 Cr | -914.3400 Cr | 30.2600 Cr | 34.2600 Cr | 26.8900 Cr | 75.3500 Cr | -876.8400 Cr | 1,083.8500 Cr | 270.2400 Cr | -85.8600 Cr | -174.3300 Cr |
| 2021-03-31 | 733.0000 Cr | -940.9900 Cr | 254.7000 Cr | 44.2300 Cr | 46.7700 Cr | 48.4600 Cr | -688.7700 Cr | 1,301.1100 Cr | 391.0700 Cr | -75.0400 Cr | -660.1700 Cr |
| 2020-03-31 | 347.4130 Cr | -221.1240 Cr | -127.6550 Cr | 125.2270 Cr | -1.2800 Cr | 1.6880 Cr | -222.1860 Cr | 293.6110 Cr | -3.2600 Cr | -38.5810 Cr | -223.2320 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 1,415.05 Cr | 610.15 Cr | 804.90 Cr | 0.5688 | 179.06 Cr | 92.30 Cr | 1.71 | 294.57 Cr | 0.0652 |
| 2024-09-30 | 1,223.70 Cr | 548.30 Cr | 675.40 Cr | 0.5519 | 70.82 Cr | 19.84 Cr | 0.37 | 182.93 Cr | 0.0162 |
| 2024-06-30 | 1,194.91 Cr | 816.89 Cr | 378.02 Cr | 0.3164 | 65.14 Cr | 12.51 Cr | 0.23 | 159.65 Cr | 0.0105 |
| 2024-03-31 | 1,439.67 Cr | 985.37 Cr | 454.30 Cr | 0.3156 | 139.24 Cr | 75.61 Cr | 1.40 | 260.02 Cr | 0.0525 |
| 2023-12-31 | 1,194.92 Cr | 545.41 Cr | 649.51 Cr | 0.5436 | 85.44 Cr | 23.14 Cr | 0.43 | 183.85 Cr | 0.0194 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 43.22 Cr | 8.65 Cr | 51.87 Cr | 0.00 Cr | 2,107.13 Cr | 4,119.71 Cr | 4,094.02 Cr | 8,729.28 Cr | 4,585.12 Cr |
| 2024-06-30 | -141.65 Cr | 283.30 Cr | 141.65 Cr | 0.00 Cr | 0.00 Cr | 141.65 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 141.65 Cr | 11.53 Cr | 141.65 Cr | 1,695.20 Cr | 1,845.41 Cr | 3,834.97 Cr | 4,047.53 Cr | 8,387.03 Cr | 4,271.46 Cr |
| 2023-12-31 | -67.16 Cr | 134.32 Cr | 67.16 Cr | 0.00 Cr | 0.00 Cr | 67.16 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 66.74 Cr | 15.21 Cr | 81.95 Cr | 1,548.75 Cr | 1,865.53 Cr | 3,667.93 Cr | 3,914.91 Cr | 8,057.63 Cr | 4,014.57 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 12.51 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 75.61 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 23.14 Cr | 196.82 Cr | 0.00 Cr | 0.00 Cr | 196.82 Cr | 263.98 Cr | 67.16 Cr | 0.00 Cr | 196.82 Cr |
| 2023-09-30 | 36.95 Cr | 186.74 Cr | 0.00 Cr | 0.00 Cr | 186.74 Cr | 67.16 Cr | -119.58 Cr | 0.00 Cr | 186.74 Cr |
| 2023-06-30 | 24.85 Cr | 181.10 Cr | 0.00 Cr | 0.00 Cr | 181.10 Cr | 227.05 Cr | 45.95 Cr | 0.00 Cr | 181.10 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2020-09-29 | September 29, 20 | 5:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,744.90 | ₹4,186,497,390,360.00 | ₹1,539,404.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,891.50 | ₹1,564,008,080,155.00 | ₹717,304.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,254.60 | ₹1,101,504,496,478.00 | ₹168,941.00 |
| Mankind Pharma Limited | MANKIND | ₹2,588.40 | ₹1,067,918,241,168.00 | ₹342,053.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,177.40 | ₹980,907,622,968.00 | ₹1,938,682.00 |
| Lupin Limited | LUPIN | ₹2,009.20 | ₹917,330,458,276.00 | ₹966,589.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹845.35 | ₹850,616,530,500.00 | ₹1,860,605.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,201.20 | ₹697,658,929,968.00 | ₹653,310.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,000.40 | ₹597,872,826,000.00 | ₹97,948.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,368.80 | ₹386,259,126,032.00 | ₹2,163,260.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,423.80 | ₹361,224,068,436.00 | ₹163,712.00 |
| Laurus Labs Limited | LAURUSLABS | ₹640.35 | ₹345,310,338,375.00 | ₹1,671,228.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,679.20 | ₹334,664,498,320.00 | ₹44,703.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,202.20 | ₹306,037,994,912.00 | ₹330,131.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,658.70 | ₹258,221,804,814.00 | ₹100,079.00 |
| Piramal Enterprises Limited | PEL | ₹1,039.85 | ₹234,462,986,345.00 | ₹552,041.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,401.40 | ₹227,698,028,558.00 | ₹264,593.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,727.50 | ₹218,187,500,000.00 | ₹13,476.00 |
| Eris Lifesciences Limited | ERIS | ₹1,382.90 | ₹188,299,218,053.00 | ₹81,150.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,136.00 | ₹168,533,566,400.00 | ₹53,273.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹849.65 | ₹167,009,863,405.00 | ₹223,768.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹829.80 | ₹148,625,361,828.00 | ₹383,129.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹915.95 | ₹145,893,560,183.00 | ₹228,298.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,906.70 | ₹144,931,500,763.00 | ₹146,966.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹480.20 | ₹116,469,494,344.00 | ₹1,207,487.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,223.50 | ₹86,706,866,654.00 | ₹3,571.00 |
| FDC Limited | FDC | ₹430.60 | ₹70,106,024,754.00 | ₹67,489.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹712.85 | ₹64,608,888,867.00 | ₹374,808.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹658.10 | ₹64,356,197,871.00 | ₹163,074.00 |
| Strides Pharma Science Limited | STAR | ₹640.75 | ₹59,053,256,433.00 | ₹243,236.00 |
| Innova Captab Limited | INNOVACAP | ₹915.85 | ₹52,409,452,141.00 | ₹37,786.00 |
| Hikal Limited | HIKAL | ₹423.80 | ₹52,254,857,850.00 | ₹371,223.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹152.84 | ₹49,599,942,480.00 | ₹505,473.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹633.90 | ₹44,630,236,620.00 | ₹75,809.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹799.75 | ₹40,562,604,224.00 | ₹101,985.00 |
| Sequent Scientific Limited | SEQUENT | ₹148.17 | ₹37,087,247,340.00 | ₹527,793.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,179.20 | ₹36,041,821,488.00 | ₹10,217.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹349.90 | ₹35,087,098,650.00 | ₹40,163.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹361.65 | ₹33,007,795,500.00 | ₹101,872.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹53.91 | ₹29,540,183,967.00 | ₹4,747,370.00 |
| Suven Life Sciences Limited | SUVEN | ₹127.13 | ₹27,723,712,024.00 | ₹173,057.00 |
| Alembic Limited | ALEMBICLTD | ₹105.35 | ₹27,051,965,791.00 | ₹436,085.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹520.70 | ₹25,021,207,514.00 | ₹37,558.00 |
Key Executives
Executive Vice President of Manufacturing & Operations
Mr. B. V. R. K. Suryadevara Srinivasa Rao
Gender: male
Year Born: 1968
Chief Financial Officer & Whole-Time Director
Mr. Vantaram Venkata Ravi Kumar Dip in Mgmt., DIS, F.C.M.A.
Gender: male
Year Born: 1965
Head of Quality & Executive Director
Dr. Lakshmana Rao Venkata Chunduru M.Sc., Ph.D.
Gender: Not Specified
Year Born: 1962
Executive Vice President of Synthesis
Mr. Dammalapati Venkata Lakshmi Narasimha Rao
Gender: male
Year Born: 1969
Executive Vice President, Head of Synthesis & Ingredients and Executive Director
Mr. Krishna Chaitanya Chava
Gender: male
Year Born: 1990
Executive Vice President of Portfolio Management
Mr. Rajaram Iyer M.B.A.
Gender: male
Year Born: 1974
Executive Vice President of Finance
Mr. Chagarlamudi Sita Ramaiah
Gender: male
Year Born: 1973
Executive Vice President of Human Resources
Mr. Narasimha Rao Chava
Gender: male
Year Born: 1968
Chief Executive Officer & Whole Time Director
Dr. Satyanarayana Chava M.Sc., Ph.D.
Gender: Not Specified
Year Born: 1961
Executive Vice President of Manufacturing
Mr. Srinivasa Rao Suryadevara B.Sc, M.Sc.
Gender: male
Year Born: 1963
FAQs about Laurus Labs Limited
Who is the CEO of the company?
The CEO is Dr. Satyanarayana Chava M.Sc., Ph.D..
What is the current market price of the stock?
The current price is ₹640.35.
What is the 52-week price range?
The range is ₹385.45-646.2.
What is the market capitalization of the company?
The market capitalization is ₹34,531.03 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 172.60.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Laurus Labs Limited (ISIN: INE947Q01028) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹34,531.03 crores and an average daily volume of 3,204,786 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.8.